MedPath

Liver Regeneration Therapy by Intrahepatic Arterial Administration of Autologous Adipose Tissue Derived Stromal Cells

Not Applicable
Completed
Conditions
Liver Cirrhosis
Interventions
Biological: adipose tissue derived stromal cells dosage
Registration Number
NCT01062750
Lead Sponsor
Kanazawa University
Brief Summary

Mesenchymal stem cells have capability to differentiate into hepatocyte and will be useful for liver regeneration. Adipose tissue is relatively enriched with mesenchymal stem cell compared to bone marrow tissue. In this trial, eligible liver cirrhosis patients will receive autologous adipose tissue derived stromal cells through intrahepatic arterial catheterization.

Detailed Description

The population of the liver cirrhosis patients is enormous in Japan and the only radical treatment for them is liver transplantation: however, the number of giving donor is extremely limited. Mesenchymal stem cells have been capable to differentiate into mesodermal-lineage cells as well as endodermal-lineage cells such as hepatocytes. They reside in the mesenchymal tissues such as bone marrows as well as adipose tissues. The latter tissues are relatively enriched with mesenchymal stem cells compared to bone marrow cells. In this study, the cirrhotic patients will undergo intrahepatic arterial administration of autologous adipose tissue derived stromal cells through catheter.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
4
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
adipose tissue derived stromal cellsadipose tissue derived stromal cells dosage-
Primary Outcome Measures
NameTimeMethod
all cause harmful eventsone month
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Kanazawa University Hospital

🇯🇵

Kanazawa, Ishikawa, Japan

© Copyright 2025. All Rights Reserved by MedPath